nodes	percent_of_prediction	percent_of_DWPC	metapath
MACITENTAN—CYP2C19—prostate cancer	0.205	0.611	CbGaD
MACITENTAN—CYP3A4—prostate cancer	0.13	0.389	CbGaD
MACITENTAN—ALB—Abiraterone—prostate cancer	0.0521	0.115	CbGbCtD
MACITENTAN—CYP2C19—Bicalutamide—prostate cancer	0.0407	0.09	CbGbCtD
MACITENTAN—CYP2C19—Nilutamide—prostate cancer	0.0407	0.09	CbGbCtD
MACITENTAN—ALB—Estrone—prostate cancer	0.0376	0.0832	CbGbCtD
MACITENTAN—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0375	0.0828	CbGbCtD
MACITENTAN—CYP2C19—Flutamide—prostate cancer	0.0337	0.0746	CbGbCtD
MACITENTAN—ALB—Estradiol—prostate cancer	0.0216	0.0478	CbGbCtD
MACITENTAN—CYP3A4—Bicalutamide—prostate cancer	0.0197	0.0435	CbGbCtD
MACITENTAN—ALB—Prednisone—prostate cancer	0.0186	0.0411	CbGbCtD
MACITENTAN—CYP3A4—Estramustine—prostate cancer	0.0183	0.0405	CbGbCtD
MACITENTAN—CYP3A4—Flutamide—prostate cancer	0.0163	0.0361	CbGbCtD
MACITENTAN—CYP3A4—Abiraterone—prostate cancer	0.0163	0.0361	CbGbCtD
MACITENTAN—CYP2C19—Estradiol—prostate cancer	0.014	0.031	CbGbCtD
MACITENTAN—CYP3A4—Cabazitaxel—prostate cancer	0.0121	0.0267	CbGbCtD
MACITENTAN—CYP2C19—Prednisone—prostate cancer	0.0121	0.0266	CbGbCtD
MACITENTAN—CYP3A4—Estrone—prostate cancer	0.0118	0.0261	CbGbCtD
MACITENTAN—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0105	0.0232	CbGbCtD
MACITENTAN—CYP3A4—Conjugated Estrogens—prostate cancer	0.00772	0.0171	CbGbCtD
MACITENTAN—CYP3A4—Mitoxantrone—prostate cancer	0.00701	0.0155	CbGbCtD
MACITENTAN—CYP3A4—Estradiol—prostate cancer	0.00677	0.015	CbGbCtD
MACITENTAN—CYP3A4—Prednisone—prostate cancer	0.00583	0.0129	CbGbCtD
MACITENTAN—CYP3A4—Etoposide—prostate cancer	0.00442	0.00978	CbGbCtD
MACITENTAN—CYP3A4—Docetaxel—prostate cancer	0.00405	0.00895	CbGbCtD
MACITENTAN—EDNRB—prostate gland—prostate cancer	0.00351	0.139	CbGeAlD
MACITENTAN—CYP2C19—urine—prostate cancer	0.00345	0.137	CbGeAlD
MACITENTAN—CYP3A4—Doxorubicin—prostate cancer	0.00302	0.00667	CbGbCtD
MACITENTAN—EDNRA—prostate gland—prostate cancer	0.0029	0.115	CbGeAlD
MACITENTAN—Hepatotoxicity—Abiraterone—prostate cancer	0.00283	0.033	CcSEcCtD
MACITENTAN—EDNRA—seminal vesicle—prostate cancer	0.00245	0.0974	CbGeAlD
MACITENTAN—EDNRB—urethra—prostate cancer	0.00235	0.0933	CbGeAlD
MACITENTAN—Fluid retention—Abiraterone—prostate cancer	0.00207	0.0242	CcSEcCtD
MACITENTAN—CYP3A4—urine—prostate cancer	0.00204	0.081	CbGeAlD
MACITENTAN—EDNRA—urethra—prostate cancer	0.00194	0.0771	CbGeAlD
MACITENTAN—Hepatotoxicity—Bicalutamide—prostate cancer	0.00187	0.0218	CcSEcCtD
MACITENTAN—EDNRB—testis—prostate cancer	0.00155	0.0614	CbGeAlD
MACITENTAN—Nasopharyngitis—Abiraterone—prostate cancer	0.00142	0.0165	CcSEcCtD
MACITENTAN—EDNRA—testis—prostate cancer	0.00128	0.0507	CbGeAlD
MACITENTAN—Influenza—Nilutamide—prostate cancer	0.00125	0.0146	CcSEcCtD
MACITENTAN—Infestation NOS—Abiraterone—prostate cancer	0.00122	0.0143	CcSEcCtD
MACITENTAN—Infestation—Abiraterone—prostate cancer	0.00122	0.0143	CcSEcCtD
MACITENTAN—Urinary tract infection—Abiraterone—prostate cancer	0.00119	0.0139	CcSEcCtD
MACITENTAN—Fluid retention—Ethinyl Estradiol—prostate cancer	0.00116	0.0135	CcSEcCtD
MACITENTAN—EDNRB—lymph node—prostate cancer	0.00112	0.0445	CbGeAlD
MACITENTAN—Urinary tract infection—Nilutamide—prostate cancer	0.00109	0.0127	CcSEcCtD
MACITENTAN—Influenza—Cabazitaxel—prostate cancer	0.00105	0.0123	CcSEcCtD
MACITENTAN—Angiopathy—Abiraterone—prostate cancer	0.000996	0.0116	CcSEcCtD
MACITENTAN—Urinary tract infection—Degarelix—prostate cancer	0.00097	0.0113	CcSEcCtD
MACITENTAN—Fluid retention—Conjugated Estrogens—prostate cancer	0.000943	0.011	CcSEcCtD
MACITENTAN—Infestation NOS—Cabazitaxel—prostate cancer	0.00094	0.011	CcSEcCtD
MACITENTAN—Infestation—Cabazitaxel—prostate cancer	0.00094	0.011	CcSEcCtD
MACITENTAN—EDNRA—lymph node—prostate cancer	0.000926	0.0368	CbGeAlD
MACITENTAN—Urinary tract infection—Cabazitaxel—prostate cancer	0.000914	0.0107	CcSEcCtD
MACITENTAN—Influenza—Bicalutamide—prostate cancer	0.000904	0.0105	CcSEcCtD
MACITENTAN—Anaemia—Abiraterone—prostate cancer	0.000883	0.0103	CcSEcCtD
MACITENTAN—Bronchitis—Bicalutamide—prostate cancer	0.00087	0.0101	CcSEcCtD
MACITENTAN—Angiopathy—Degarelix—prostate cancer	0.000813	0.00947	CcSEcCtD
MACITENTAN—Anaemia—Nilutamide—prostate cancer	0.000807	0.00941	CcSEcCtD
MACITENTAN—Anaemia—Flutamide—prostate cancer	0.000803	0.00936	CcSEcCtD
MACITENTAN—Oedema—Estramustine—prostate cancer	0.000803	0.00936	CcSEcCtD
MACITENTAN—Hepatotoxicity—Etoposide—prostate cancer	0.000798	0.0093	CcSEcCtD
MACITENTAN—Urinary tract infection—Bicalutamide—prostate cancer	0.000784	0.00914	CcSEcCtD
MACITENTAN—Oedema—Abiraterone—prostate cancer	0.00078	0.00909	CcSEcCtD
MACITENTAN—Infection—Abiraterone—prostate cancer	0.000775	0.00903	CcSEcCtD
MACITENTAN—Oedema—Estrone—prostate cancer	0.000767	0.00894	CcSEcCtD
MACITENTAN—Angiopathy—Cabazitaxel—prostate cancer	0.000766	0.00893	CcSEcCtD
MACITENTAN—Fluid retention—Estradiol—prostate cancer	0.000755	0.0088	CcSEcCtD
MACITENTAN—Bronchitis—Ethinyl Estradiol—prostate cancer	0.000735	0.00857	CcSEcCtD
MACITENTAN—Anaemia—Degarelix—prostate cancer	0.000721	0.0084	CcSEcCtD
MACITENTAN—Pharyngitis—Bicalutamide—prostate cancer	0.000718	0.00838	CcSEcCtD
MACITENTAN—Oedema—Nilutamide—prostate cancer	0.000712	0.00831	CcSEcCtD
MACITENTAN—Oedema—Flutamide—prostate cancer	0.000709	0.00827	CcSEcCtD
MACITENTAN—Infestation NOS—Ethinyl Estradiol—prostate cancer	0.000682	0.00795	CcSEcCtD
MACITENTAN—Infestation—Ethinyl Estradiol—prostate cancer	0.000682	0.00795	CcSEcCtD
MACITENTAN—Anaemia—Cabazitaxel—prostate cancer	0.000679	0.00792	CcSEcCtD
MACITENTAN—ALB—testis—prostate cancer	0.000677	0.0269	CbGeAlD
MACITENTAN—Oedema—Estradiol valerate/Dienogest—prostate cancer	0.000669	0.0078	CcSEcCtD
MACITENTAN—Hepatotoxicity—Docetaxel—prostate cancer	0.000663	0.00773	CcSEcCtD
MACITENTAN—Urinary tract infection—Ethinyl Estradiol—prostate cancer	0.000662	0.00772	CcSEcCtD
MACITENTAN—Angiopathy—Bicalutamide—prostate cancer	0.000657	0.00766	CcSEcCtD
MACITENTAN—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.000656	0.00765	CcSEcCtD
MACITENTAN—Hepatotoxicity—Capecitabine—prostate cancer	0.000642	0.00748	CcSEcCtD
MACITENTAN—Influenza—Goserelin—prostate cancer	0.000629	0.00733	CcSEcCtD
MACITENTAN—Nervous system disorder—Degarelix—prostate cancer	0.000624	0.00728	CcSEcCtD
MACITENTAN—Influenza—Conjugated Estrogens—prostate cancer	0.000623	0.00726	CcSEcCtD
MACITENTAN—Pharyngitis—Ethinyl Estradiol—prostate cancer	0.000607	0.00708	CcSEcCtD
MACITENTAN—Bronchitis—Goserelin—prostate cancer	0.000605	0.00705	CcSEcCtD
MACITENTAN—Oedema—Cabazitaxel—prostate cancer	0.000599	0.00699	CcSEcCtD
MACITENTAN—Bronchitis—Conjugated Estrogens—prostate cancer	0.000599	0.00699	CcSEcCtD
MACITENTAN—Infection—Cabazitaxel—prostate cancer	0.000596	0.00694	CcSEcCtD
MACITENTAN—Hypotension—Degarelix—prostate cancer	0.000595	0.00693	CcSEcCtD
MACITENTAN—Nervous system disorder—Cabazitaxel—prostate cancer	0.000588	0.00685	CcSEcCtD
MACITENTAN—Anaemia—Bicalutamide—prostate cancer	0.000582	0.00679	CcSEcCtD
MACITENTAN—Hypotension—Cabazitaxel—prostate cancer	0.00056	0.00653	CcSEcCtD
MACITENTAN—Infestation—Conjugated Estrogens—prostate cancer	0.000556	0.00648	CcSEcCtD
MACITENTAN—Infestation NOS—Conjugated Estrogens—prostate cancer	0.000556	0.00648	CcSEcCtD
MACITENTAN—Angiopathy—Ethinyl Estradiol—prostate cancer	0.000555	0.00647	CcSEcCtD
MACITENTAN—Urinary tract infection—Goserelin—prostate cancer	0.000545	0.00636	CcSEcCtD
MACITENTAN—Nasopharyngitis—Estradiol—prostate cancer	0.000516	0.00602	CcSEcCtD
MACITENTAN—Oedema—Bicalutamide—prostate cancer	0.000514	0.006	CcSEcCtD
MACITENTAN—Infection—Bicalutamide—prostate cancer	0.000511	0.00596	CcSEcCtD
MACITENTAN—Nervous system disorder—Bicalutamide—prostate cancer	0.000504	0.00588	CcSEcCtD
MACITENTAN—Headache—Estramustine—prostate cancer	0.000503	0.00586	CcSEcCtD
MACITENTAN—Pharyngitis—Goserelin—prostate cancer	0.0005	0.00583	CcSEcCtD
MACITENTAN—Influenza—Estradiol—prostate cancer	0.000499	0.00581	CcSEcCtD
MACITENTAN—CYP3A4—renal system—prostate cancer	0.000499	0.0198	CbGeAlD
MACITENTAN—Pharyngitis—Conjugated Estrogens—prostate cancer	0.000495	0.00577	CcSEcCtD
MACITENTAN—ALB—lymph node—prostate cancer	0.000491	0.0195	CbGeAlD
MACITENTAN—Fluid retention—Docetaxel—prostate cancer	0.000486	0.00567	CcSEcCtD
MACITENTAN—Headache—Estrone—prostate cancer	0.00048	0.0056	CcSEcCtD
MACITENTAN—Bronchitis—Estradiol—prostate cancer	0.00048	0.00559	CcSEcCtD
MACITENTAN—Fluid retention—Capecitabine—prostate cancer	0.000471	0.00549	CcSEcCtD
MACITENTAN—Angiopathy—Goserelin—prostate cancer	0.000457	0.00533	CcSEcCtD
MACITENTAN—Angiopathy—Conjugated Estrogens—prostate cancer	0.000452	0.00528	CcSEcCtD
MACITENTAN—Headache—Nilutamide—prostate cancer	0.000446	0.0052	CcSEcCtD
MACITENTAN—Infestation NOS—Estradiol—prostate cancer	0.000445	0.00518	CcSEcCtD
MACITENTAN—Infestation—Estradiol—prostate cancer	0.000445	0.00518	CcSEcCtD
MACITENTAN—Headache—Flutamide—prostate cancer	0.000444	0.00518	CcSEcCtD
MACITENTAN—Oedema—Ethinyl Estradiol—prostate cancer	0.000435	0.00507	CcSEcCtD
MACITENTAN—Urinary tract infection—Estradiol—prostate cancer	0.000432	0.00504	CcSEcCtD
MACITENTAN—Infection—Ethinyl Estradiol—prostate cancer	0.000432	0.00503	CcSEcCtD
MACITENTAN—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.000426	0.00497	CcSEcCtD
MACITENTAN—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000419	0.00489	CcSEcCtD
MACITENTAN—Fluid retention—Prednisone—prostate cancer	0.000419	0.00489	CcSEcCtD
MACITENTAN—Anaemia—Goserelin—prostate cancer	0.000405	0.00472	CcSEcCtD
MACITENTAN—Urinary tract infection—Mitoxantrone—prostate cancer	0.000403	0.0047	CcSEcCtD
MACITENTAN—Headache—Degarelix—prostate cancer	0.000399	0.00465	CcSEcCtD
MACITENTAN—Pharyngitis—Estradiol—prostate cancer	0.000396	0.00462	CcSEcCtD
MACITENTAN—Headache—Cabazitaxel—prostate cancer	0.000376	0.00438	CcSEcCtD
MACITENTAN—Pharyngitis—Mitoxantrone—prostate cancer	0.000369	0.0043	CcSEcCtD
MACITENTAN—Angiopathy—Estradiol—prostate cancer	0.000362	0.00422	CcSEcCtD
MACITENTAN—Oedema—Goserelin—prostate cancer	0.000358	0.00417	CcSEcCtD
MACITENTAN—Infection—Goserelin—prostate cancer	0.000355	0.00414	CcSEcCtD
MACITENTAN—Oedema—Conjugated Estrogens—prostate cancer	0.000354	0.00413	CcSEcCtD
MACITENTAN—Infection—Conjugated Estrogens—prostate cancer	0.000352	0.0041	CcSEcCtD
MACITENTAN—Nervous system disorder—Goserelin—prostate cancer	0.000351	0.00409	CcSEcCtD
MACITENTAN—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000347	0.00405	CcSEcCtD
MACITENTAN—Infestation—Etoposide—prostate cancer	0.000345	0.00402	CcSEcCtD
MACITENTAN—Infestation NOS—Etoposide—prostate cancer	0.000345	0.00402	CcSEcCtD
MACITENTAN—Hypotension—Goserelin—prostate cancer	0.000334	0.0039	CcSEcCtD
MACITENTAN—Nasopharyngitis—Docetaxel—prostate cancer	0.000332	0.00387	CcSEcCtD
MACITENTAN—Hypotension—Conjugated Estrogens—prostate cancer	0.000331	0.00386	CcSEcCtD
MACITENTAN—Fluid retention—Epirubicin—prostate cancer	0.000328	0.00382	CcSEcCtD
MACITENTAN—Headache—Bicalutamide—prostate cancer	0.000322	0.00376	CcSEcCtD
MACITENTAN—Nasopharyngitis—Capecitabine—prostate cancer	0.000322	0.00375	CcSEcCtD
MACITENTAN—Influenza—Capecitabine—prostate cancer	0.000311	0.00363	CcSEcCtD
MACITENTAN—Fluid retention—Doxorubicin—prostate cancer	0.000303	0.00354	CcSEcCtD
MACITENTAN—Anaemia—Mitoxantrone—prostate cancer	0.000299	0.00349	CcSEcCtD
MACITENTAN—Bronchitis—Capecitabine—prostate cancer	0.000299	0.00349	CcSEcCtD
MACITENTAN—Infestation NOS—Docetaxel—prostate cancer	0.000286	0.00334	CcSEcCtD
MACITENTAN—Infestation—Docetaxel—prostate cancer	0.000286	0.00334	CcSEcCtD
MACITENTAN—Oedema—Estradiol—prostate cancer	0.000284	0.00331	CcSEcCtD
MACITENTAN—Infection—Estradiol—prostate cancer	0.000282	0.00328	CcSEcCtD
MACITENTAN—Angiopathy—Etoposide—prostate cancer	0.000281	0.00327	CcSEcCtD
MACITENTAN—Nervous system disorder—Estradiol—prostate cancer	0.000278	0.00324	CcSEcCtD
MACITENTAN—Infestation NOS—Capecitabine—prostate cancer	0.000277	0.00323	CcSEcCtD
MACITENTAN—Infestation—Capecitabine—prostate cancer	0.000277	0.00323	CcSEcCtD
MACITENTAN—Headache—Ethinyl Estradiol—prostate cancer	0.000272	0.00317	CcSEcCtD
MACITENTAN—Urinary tract infection—Capecitabine—prostate cancer	0.00027	0.00314	CcSEcCtD
MACITENTAN—Oedema—Mitoxantrone—prostate cancer	0.000264	0.00308	CcSEcCtD
MACITENTAN—Infection—Mitoxantrone—prostate cancer	0.000263	0.00306	CcSEcCtD
MACITENTAN—Pharyngitis—Docetaxel—prostate cancer	0.000255	0.00298	CcSEcCtD
MACITENTAN—Anaemia—Etoposide—prostate cancer	0.000249	0.0029	CcSEcCtD
MACITENTAN—Pharyngitis—Capecitabine—prostate cancer	0.000247	0.00288	CcSEcCtD
MACITENTAN—Hypotension—Mitoxantrone—prostate cancer	0.000247	0.00288	CcSEcCtD
MACITENTAN—Angiopathy—Docetaxel—prostate cancer	0.000233	0.00272	CcSEcCtD
MACITENTAN—Angiopathy—Capecitabine—prostate cancer	0.000226	0.00263	CcSEcCtD
MACITENTAN—Nasopharyngitis—Epirubicin—prostate cancer	0.000224	0.00261	CcSEcCtD
MACITENTAN—Headache—Goserelin—prostate cancer	0.000224	0.00261	CcSEcCtD
MACITENTAN—Headache—Conjugated Estrogens—prostate cancer	0.000222	0.00259	CcSEcCtD
MACITENTAN—Infection—Etoposide—prostate cancer	0.000218	0.00255	CcSEcCtD
MACITENTAN—Influenza—Epirubicin—prostate cancer	0.000217	0.00253	CcSEcCtD
MACITENTAN—Bronchitis—Epirubicin—prostate cancer	0.000208	0.00243	CcSEcCtD
MACITENTAN—Nasopharyngitis—Doxorubicin—prostate cancer	0.000207	0.00242	CcSEcCtD
MACITENTAN—Anaemia—Docetaxel—prostate cancer	0.000207	0.00241	CcSEcCtD
MACITENTAN—Hypotension—Etoposide—prostate cancer	0.000205	0.00239	CcSEcCtD
MACITENTAN—Angiopathy—Prednisone—prostate cancer	0.000201	0.00235	CcSEcCtD
MACITENTAN—Influenza—Doxorubicin—prostate cancer	0.0002	0.00234	CcSEcCtD
MACITENTAN—Anaemia—Capecitabine—prostate cancer	0.0002	0.00234	CcSEcCtD
MACITENTAN—Infestation NOS—Epirubicin—prostate cancer	0.000193	0.00225	CcSEcCtD
MACITENTAN—Infestation—Epirubicin—prostate cancer	0.000193	0.00225	CcSEcCtD
MACITENTAN—Bronchitis—Doxorubicin—prostate cancer	0.000193	0.00225	CcSEcCtD
MACITENTAN—Urinary tract infection—Epirubicin—prostate cancer	0.000188	0.00219	CcSEcCtD
MACITENTAN—Oedema—Docetaxel—prostate cancer	0.000183	0.00213	CcSEcCtD
MACITENTAN—Infection—Docetaxel—prostate cancer	0.000181	0.00212	CcSEcCtD
MACITENTAN—Nervous system disorder—Docetaxel—prostate cancer	0.000179	0.00209	CcSEcCtD
MACITENTAN—Infestation NOS—Doxorubicin—prostate cancer	0.000179	0.00208	CcSEcCtD
MACITENTAN—Infestation—Doxorubicin—prostate cancer	0.000179	0.00208	CcSEcCtD
MACITENTAN—Anaemia—Prednisone—prostate cancer	0.000178	0.00208	CcSEcCtD
MACITENTAN—Headache—Estradiol—prostate cancer	0.000178	0.00207	CcSEcCtD
MACITENTAN—Oedema—Capecitabine—prostate cancer	0.000177	0.00206	CcSEcCtD
MACITENTAN—Infection—Capecitabine—prostate cancer	0.000176	0.00205	CcSEcCtD
MACITENTAN—Urinary tract infection—Doxorubicin—prostate cancer	0.000174	0.00203	CcSEcCtD
MACITENTAN—Nervous system disorder—Capecitabine—prostate cancer	0.000173	0.00202	CcSEcCtD
MACITENTAN—Pharyngitis—Epirubicin—prostate cancer	0.000172	0.00201	CcSEcCtD
MACITENTAN—Hypotension—Docetaxel—prostate cancer	0.000171	0.00199	CcSEcCtD
MACITENTAN—Headache—Mitoxantrone—prostate cancer	0.000166	0.00193	CcSEcCtD
MACITENTAN—Hypotension—Capecitabine—prostate cancer	0.000165	0.00193	CcSEcCtD
MACITENTAN—Pharyngitis—Doxorubicin—prostate cancer	0.000159	0.00186	CcSEcCtD
MACITENTAN—Oedema—Prednisone—prostate cancer	0.000158	0.00184	CcSEcCtD
MACITENTAN—Angiopathy—Epirubicin—prostate cancer	0.000157	0.00183	CcSEcCtD
MACITENTAN—Infection—Prednisone—prostate cancer	0.000156	0.00182	CcSEcCtD
MACITENTAN—Nervous system disorder—Prednisone—prostate cancer	0.000154	0.0018	CcSEcCtD
MACITENTAN—Angiopathy—Doxorubicin—prostate cancer	0.000146	0.0017	CcSEcCtD
MACITENTAN—Anaemia—Epirubicin—prostate cancer	0.00014	0.00163	CcSEcCtD
MACITENTAN—Headache—Etoposide—prostate cancer	0.000138	0.00161	CcSEcCtD
MACITENTAN—Anaemia—Doxorubicin—prostate cancer	0.000129	0.00151	CcSEcCtD
MACITENTAN—Oedema—Epirubicin—prostate cancer	0.000123	0.00144	CcSEcCtD
MACITENTAN—Infection—Epirubicin—prostate cancer	0.000122	0.00143	CcSEcCtD
MACITENTAN—Nervous system disorder—Epirubicin—prostate cancer	0.000121	0.00141	CcSEcCtD
MACITENTAN—Hypotension—Epirubicin—prostate cancer	0.000115	0.00134	CcSEcCtD
MACITENTAN—Headache—Docetaxel—prostate cancer	0.000114	0.00133	CcSEcCtD
MACITENTAN—Oedema—Doxorubicin—prostate cancer	0.000114	0.00133	CcSEcCtD
MACITENTAN—Infection—Doxorubicin—prostate cancer	0.000113	0.00132	CcSEcCtD
MACITENTAN—Nervous system disorder—Doxorubicin—prostate cancer	0.000112	0.0013	CcSEcCtD
MACITENTAN—Headache—Capecitabine—prostate cancer	0.000111	0.00129	CcSEcCtD
MACITENTAN—Hypotension—Doxorubicin—prostate cancer	0.000107	0.00124	CcSEcCtD
MACITENTAN—Headache—Prednisone—prostate cancer	9.87e-05	0.00115	CcSEcCtD
MACITENTAN—Headache—Epirubicin—prostate cancer	7.72e-05	0.0009	CcSEcCtD
MACITENTAN—Headache—Doxorubicin—prostate cancer	7.14e-05	0.000833	CcSEcCtD
MACITENTAN—CYP2C19—Metabolism—GSTA1—prostate cancer	8.09e-06	7.95e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—ERBB2—prostate cancer	8.07e-06	7.93e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—PIK3CG—prostate cancer	8.06e-06	7.92e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.06e-06	7.92e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—HSD3B2—prostate cancer	8e-06	7.86e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NAT2—prostate cancer	8e-06	7.86e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—GSTO1—prostate cancer	8e-06	7.86e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—MYC—prostate cancer	7.99e-06	7.86e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—TGFB1—prostate cancer	7.97e-06	7.84e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—EGF—prostate cancer	7.97e-06	7.83e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—PIK3CB—prostate cancer	7.97e-06	7.83e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—SULT2A1—prostate cancer	7.94e-06	7.81e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—EGFR—prostate cancer	7.82e-06	7.68e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—MED12—prostate cancer	7.81e-06	7.68e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—GNG5—prostate cancer	7.75e-06	7.62e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	7.69e-06	7.56e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP2C18—prostate cancer	7.67e-06	7.54e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—LRP2—prostate cancer	7.67e-06	7.54e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PLCB2—prostate cancer	7.67e-06	7.54e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CXCL8—prostate cancer	7.65e-06	7.52e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—P4HB—prostate cancer	7.52e-06	7.39e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CDKN1B—prostate cancer	7.48e-06	7.35e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—CREBBP—prostate cancer	7.47e-06	7.34e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—NCOA3—prostate cancer	7.47e-06	7.34e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—HPGD—prostate cancer	7.46e-06	7.34e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—B4GALT4—prostate cancer	7.46e-06	7.34e-05	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR downstream signaling—AKT1—prostate cancer	7.39e-06	7.27e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—KRAS—prostate cancer	7.38e-06	7.26e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—IGF1—prostate cancer	7.38e-06	7.25e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.34e-06	7.21e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CASP3—prostate cancer	7.33e-06	7.2e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—SLC22A1—prostate cancer	7.32e-06	7.19e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—IL2—prostate cancer	7.32e-06	7.19e-05	CbGpPWpGaD
MACITENTAN—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	7.3e-06	7.18e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—IL6—prostate cancer	7.28e-06	7.15e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	7.23e-06	7.11e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CCND1—prostate cancer	7.13e-06	7.01e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—SULT2A1—prostate cancer	7.13e-06	7.01e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—HPGDS—prostate cancer	7.12e-06	7e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—PIK3CD—prostate cancer	7.08e-06	6.96e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP2C19—prostate cancer	7.08e-06	6.96e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CTNNB1—prostate cancer	7.06e-06	6.94e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—TNFRSF21—prostate cancer	7.02e-06	6.9e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—MED12—prostate cancer	7.01e-06	6.89e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—SERPINE1—prostate cancer	7.01e-06	6.89e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—GNG5—prostate cancer	6.96e-06	6.84e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—MMP9—prostate cancer	6.92e-06	6.81e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—GSTT1—prostate cancer	6.91e-06	6.79e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—ACHE—prostate cancer	6.91e-06	6.79e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CDKN1A—prostate cancer	6.9e-06	6.78e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—PTEN—prostate cancer	6.88e-06	6.77e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP2A6—prostate cancer	6.83e-06	6.71e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP7B1—prostate cancer	6.83e-06	6.71e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—MTAP—prostate cancer	6.83e-06	6.71e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.8e-06	6.69e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—PIK3CA—prostate cancer	6.78e-06	6.67e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—AKT1—prostate cancer	6.71e-06	6.6e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NCOA3—prostate cancer	6.7e-06	6.59e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—NOS3—prostate cancer	6.69e-06	6.58e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SULT1E1—prostate cancer	6.65e-06	6.54e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SRD5A1—prostate cancer	6.65e-06	6.54e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—AKR1C3—prostate cancer	6.64e-06	6.53e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PRKACB—prostate cancer	6.61e-06	6.5e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.59e-06	6.47e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—EP300—prostate cancer	6.56e-06	6.45e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—TP53—prostate cancer	6.56e-06	6.45e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP17A1—prostate cancer	6.54e-06	6.43e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—JAK2—prostate cancer	6.5e-06	6.39e-05	CbGpPWpGaD
MACITENTAN—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	6.47e-06	6.36e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.45e-06	6.34e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—HPGDS—prostate cancer	6.39e-06	6.29e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—SRC—prostate cancer	6.38e-06	6.27e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—ACSL4—prostate cancer	6.35e-06	6.24e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—HSD17B3—prostate cancer	6.35e-06	6.24e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—NCOA2—prostate cancer	6.23e-06	6.13e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—VEGFA—prostate cancer	6.22e-06	6.11e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—ACHE—prostate cancer	6.2e-06	6.1e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—GSTT1—prostate cancer	6.2e-06	6.1e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—PIK3CB—prostate cancer	6.18e-06	6.07e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—STAT3—prostate cancer	6.16e-06	6.05e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP2A6—prostate cancer	6.13e-06	6.03e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.11e-06	6e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PHGDH—prostate cancer	6.08e-06	5.98e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—UMPS—prostate cancer	6.08e-06	5.98e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—ARG2—prostate cancer	6.08e-06	5.98e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—IL6—prostate cancer	6.01e-06	5.91e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—LDHB—prostate cancer	5.97e-06	5.87e-05	CbGpPWpGaD
MACITENTAN—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	5.97e-06	5.86e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—AKR1C3—prostate cancer	5.96e-06	5.86e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—SLC5A5—prostate cancer	5.94e-06	5.84e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PRKACB—prostate cancer	5.93e-06	5.83e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP17A1—prostate cancer	5.87e-06	5.77e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP3A5—prostate cancer	5.86e-06	5.76e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP2E1—prostate cancer	5.81e-06	5.71e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.79e-06	5.69e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—NQO1—prostate cancer	5.74e-06	5.64e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—MYC—prostate cancer	5.72e-06	5.62e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—TGFB1—prostate cancer	5.71e-06	5.61e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—IL2—prostate cancer	5.67e-06	5.57e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—TH—prostate cancer	5.66e-06	5.56e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PDHA1—prostate cancer	5.66e-06	5.56e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTA3—prostate cancer	5.66e-06	5.56e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—UCP3—prostate cancer	5.66e-06	5.56e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—TCN2—prostate cancer	5.66e-06	5.56e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.62e-06	5.53e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP3A4—prostate cancer	5.6e-06	5.5e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—EGFR—prostate cancer	5.59e-06	5.5e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NCOA2—prostate cancer	5.59e-06	5.5e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.57e-06	5.48e-05	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—AKT1—prostate cancer	5.54e-06	5.45e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP1B1—prostate cancer	5.5e-06	5.41e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.4e-06	5.3e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.4e-06	5.3e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—SLC5A5—prostate cancer	5.34e-06	5.25e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—GGT1—prostate cancer	5.33e-06	5.24e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—KRAS—prostate cancer	5.29e-06	5.2e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—NCOA1—prostate cancer	5.25e-06	5.16e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP2E1—prostate cancer	5.21e-06	5.12e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP19A1—prostate cancer	5.18e-06	5.09e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTA4—prostate cancer	5.17e-06	5.09e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—TBXAS1—prostate cancer	5.17e-06	5.09e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NQO1—prostate cancer	5.15e-06	5.07e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—EP300—prostate cancer	5.09e-06	5e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—TH—prostate cancer	5.08e-06	4.99e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.05e-06	4.96e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTA2—prostate cancer	5.04e-06	4.96e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP3A4—prostate cancer	5.03e-06	4.94e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5e-06	4.92e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—RXRA—prostate cancer	4.99e-06	4.91e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SULT1A1—prostate cancer	4.98e-06	4.9e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—ABCG5—prostate cancer	4.98e-06	4.9e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—SRC—prostate cancer	4.95e-06	4.86e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP1B1—prostate cancer	4.94e-06	4.86e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTA1—prostate cancer	4.86e-06	4.78e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.86e-06	4.78e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—PIK3CA—prostate cancer	4.86e-06	4.77e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—VEGFA—prostate cancer	4.82e-06	4.74e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—COMT—prostate cancer	4.81e-06	4.73e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTO1—prostate cancer	4.81e-06	4.73e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.81e-06	4.73e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NAT2—prostate cancer	4.81e-06	4.73e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—GSTP1—prostate cancer	4.79e-06	4.71e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—GGT1—prostate cancer	4.79e-06	4.7e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NCOA1—prostate cancer	4.71e-06	4.63e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—ITPR1—prostate cancer	4.71e-06	4.63e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—TP53—prostate cancer	4.7e-06	4.62e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP19A1—prostate cancer	4.65e-06	4.57e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.63e-06	4.55e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PLCB2—prostate cancer	4.61e-06	4.53e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.61e-06	4.53e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—LRP2—prostate cancer	4.61e-06	4.53e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—P4HB—prostate cancer	4.52e-06	4.45e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—RXRA—prostate cancer	4.48e-06	4.41e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—TYMS—prostate cancer	4.45e-06	4.38e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—TGFB1—prostate cancer	4.42e-06	4.35e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—GSTM1—prostate cancer	4.4e-06	4.33e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.4e-06	4.32e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.36e-06	4.29e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—LPL—prostate cancer	4.32e-06	4.25e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—COMT—prostate cancer	4.32e-06	4.25e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—IL6—prostate cancer	4.3e-06	4.23e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—GSTP1—prostate cancer	4.3e-06	4.23e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.29e-06	4.21e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—ITPR1—prostate cancer	4.23e-06	4.16e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—MED12—prostate cancer	4.22e-06	4.15e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GNG5—prostate cancer	4.18e-06	4.11e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP1A1—prostate cancer	4.17e-06	4.1e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.16e-06	4.09e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—ERCC2—prostate cancer	4.14e-06	4.07e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—KRAS—prostate cancer	4.1e-06	4.03e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NCOA3—prostate cancer	4.03e-06	3.96e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—TYMS—prostate cancer	4e-06	3.93e-05	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—AKT1—prostate cancer	3.97e-06	3.9e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—GSTM1—prostate cancer	3.95e-06	3.88e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—MTHFR—prostate cancer	3.89e-06	3.82e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—LPL—prostate cancer	3.88e-06	3.81e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—HPGDS—prostate cancer	3.85e-06	3.78e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.82e-06	3.76e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PPARA—prostate cancer	3.82e-06	3.75e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—PIK3CA—prostate cancer	3.76e-06	3.7e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.74e-06	3.68e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—ACHE—prostate cancer	3.73e-06	3.67e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTT1—prostate cancer	3.73e-06	3.67e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—ERCC2—prostate cancer	3.71e-06	3.65e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.69e-06	3.62e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—TP53—prostate cancer	3.64e-06	3.58e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CAV1—prostate cancer	3.59e-06	3.53e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.59e-06	3.52e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PRKACB—prostate cancer	3.57e-06	3.51e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.53e-06	3.47e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—MTHFR—prostate cancer	3.49e-06	3.43e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.43e-06	3.37e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PPARA—prostate cancer	3.43e-06	3.37e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NCOA2—prostate cancer	3.36e-06	3.31e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PIK3CG—prostate cancer	3.27e-06	3.21e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CAV1—prostate cancer	3.22e-06	3.17e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.21e-06	3.15e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.13e-06	3.08e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NQO1—prostate cancer	3.1e-06	3.05e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—INS—prostate cancer	3.09e-06	3.04e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.08e-06	3.02e-05	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—AKT1—prostate cancer	3.08e-06	3.02e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—TH—prostate cancer	3.05e-06	3e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CREBBP—prostate cancer	3.03e-06	2.98e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.97e-06	2.92e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.93e-06	2.88e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GGT1—prostate cancer	2.88e-06	2.83e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PIK3CD—prostate cancer	2.87e-06	2.82e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NCOA1—prostate cancer	2.83e-06	2.79e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.79e-06	2.75e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—INS—prostate cancer	2.78e-06	2.73e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CREBBP—prostate cancer	2.72e-06	2.67e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—NOS3—prostate cancer	2.71e-06	2.67e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—RXRA—prostate cancer	2.7e-06	2.65e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—COMT—prostate cancer	2.6e-06	2.55e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTP1—prostate cancer	2.59e-06	2.54e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.58e-06	2.53e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—ITPR1—prostate cancer	2.54e-06	2.5e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PIK3CB—prostate cancer	2.5e-06	2.46e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PTGS2—prostate cancer	2.48e-06	2.44e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NOS3—prostate cancer	2.44e-06	2.39e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—TYMS—prostate cancer	2.4e-06	2.36e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—GSTM1—prostate cancer	2.38e-06	2.34e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—LPL—prostate cancer	2.33e-06	2.29e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.25e-06	2.21e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PIK3CB—prostate cancer	2.25e-06	2.21e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—ERCC2—prostate cancer	2.23e-06	2.2e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PTGS2—prostate cancer	2.23e-06	2.19e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PTEN—prostate cancer	2.16e-06	2.13e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—MTHFR—prostate cancer	2.1e-06	2.06e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—EP300—prostate cancer	2.06e-06	2.03e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PPARA—prostate cancer	2.06e-06	2.02e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PTEN—prostate cancer	1.94e-06	1.91e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CAV1—prostate cancer	1.94e-06	1.9e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—EP300—prostate cancer	1.85e-06	1.82e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.76e-06	1.73e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—INS—prostate cancer	1.67e-06	1.64e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CREBBP—prostate cancer	1.64e-06	1.61e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.55e-06	1.52e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PIK3CA—prostate cancer	1.53e-06	1.5e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NOS3—prostate cancer	1.46e-06	1.44e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.37e-06	1.35e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.35e-06	1.33e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PTGS2—prostate cancer	1.34e-06	1.32e-05	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—AKT1—prostate cancer	1.25e-06	1.23e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PTEN—prostate cancer	1.17e-06	1.15e-05	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—AKT1—prostate cancer	1.12e-06	1.1e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—EP300—prostate cancer	1.11e-06	1.09e-05	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.24e-07	8.1e-06	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—AKT1—prostate cancer	6.73e-07	6.62e-06	CbGpPWpGaD
